Generated by AI
CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company develops conditionally activated biologics through its Probody therapeutic platform, with the goal of localizing activity to the tumor microenvironment and limiting effects on healthy tissue. Its current pipeline spans multiple cancer-focused modalities, including antibody-drug conjugates, T-cell engagers, and immune-modulating therapies such as cytokines. CytomX Therapeutics also advances programs aimed at difficult-to-treat tumors, supporting research and development across a range of solid-tumor indications. Headquartered in South San Francisco, California, CytomX Therapeutics plays a specialized role in the biotechnology market as a developer of targeted cancer therapeutics designed for precision and selectivity.
Website151 Oyster Point Boulevard
South San Francisco, CA, 94080
United States
The latest articles about CTMX.
Motley Fool Press Release.
Summary of Nov 17's posts. Generated by AI.
Summary of Mar 19's posts. Generated by AI.
Summary of Mar 17's posts. Generated by AI.
Summary of Mar 19's posts. Generated by AI.
Investors talking about CTMX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.